Antibiotic resistance

Antibiotics
#Antibiotic resistance #Antimicrobial resistance (AMR) #World Health Organization

The pandemic we have trained ourselves to ignore 

Nigel Brooksby, Executive Chair at AMR Bio reinforces the warnings about antimicrobial resistance (AMR) and highlights that the threat isn’t being taken seriously enough. Antimicrobial resistance has become a familiar threat that has bred complacency  There is no shortage of evidence to show that antimicrobial resistance is one of the greatest long-term threats to global health. The scientific consensus continues to strengthen, with governments around the… Read More

#Exclusive Content

Bacteria in Petri dishes
#Antibiotic resistance #Antibiotics #Antimicrobial resistance (AMR) #Covid-19 #mRNA #mRNA-based vaccines #Oncology #RNA

How drug discovery is tackling global health challenges

This is the latest episode of the free DDW Narrated Podcast. The episode covers two articles written for DDW Volume 25, Issue 2, Spring 2024. The first article is called ‘Why more work is needed to fight antimicrobial resistance’. In the article, DDW Editor Reece Armstrong speaks to Professor… Read More

#Featured Podcasts

Female researcher in a laboratory
#Antibiotic resistance #Antibiotics #Antibody-based therapeutics #Antimicrobial resistance (AMR) #Cancer research #Carbon emissions #Environmental impact #Green lab movement #Immunotherapy #Interview #Lab technology #Molecular Biology #Oncology #Sustain #T cell activation

New podcast: Strategies and challenges in drug discovery

This is the latest episode of the free DDW narrated podcast, titled “Strategies and challenges in therapeutic development and lab practice”, which covers three articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “The inner workings of antibiotics”, “Targeting advances in immunotherapies”, and… Read More

#News

E coli bacteria
#Antibiotic resistance #Antimicrobial resistance (AMR) #Bacteria #Genetics / genomics

Scientists displace antibiotic resistance genes from bacteria

Birmingham scientists have identified essential genetic code for a method called plasmid curing, which aims to ‘displace’ antibiotic resistance genes from bacteria.   Plasmids play a crucial role in allowing bacteria to share beneficial genes rapidly in a changing environment, most concerningly when they carry genes conferring resistance… Read More

#News

Bacteria Neisseria gonorrhoeae
#Antibiotic resistance #Antibiotics #Antimicrobial resistance (AMR) #Phase III trial #SD

Gonorrhoea treatment could combat resistant infections

Newly published Phase III trial results suggest the new antibiotic gepotidacin could treat uncomplicated urogenital gonorrhoea (GC).  The trial showed that gepotidacin was non-inferior with 92.6% success rates when compared to 91.2% success rates for intramuscular ceftriaxone plus oral azithromycin combined therapy, a leading combination treatment… Read More

#News

Patient taking antibiotics
#Antibiotic resistance #Antibiotics #Antimicrobials #Bacteria #FDA #GSK #Urinary

New class of oral antibiotics for uUTIs gets FDA green light

The US Food and Drug Administration (FDA) has approved Blujepa (gepotidacin) for the treatment of female adults (≥40 kg) and paediatric patients (≥12 years, ≥40kg) with uncomplicated urinary tract infections (uUTIs).  It is approved to treat infections caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii complex,… Read More

#News #Regulatory

FDA
#Antibiotic resistance #Antibiotics #FDA #MicuRx Pharmaceutical #Orphan drugs

Novel benzoxazole antibiotic gets FDA Orphan Drug Designation

MicuRx Pharmaceutical’s anti-infection drug MRX-5 has been granted Orphan Drug Designation (ODD) by the US Food and Drug Administration (FDA) for the treatment of non-tuberculous mycobacteria (NTM) infections.  MRX-5 is a novel benzoxazole antibiotic developed for the treatment of mycobacteria infections, particularly infections caused by non-tuberculous Mycobacteria (NTM).   In recent… Read More

#News #Regulatory

Patient receiving eye drops
#Antibiotic resistance #Antibiotics #Eye health #NTC #Phase II trial

Antibiotic/NSAID combo shows potential for bacterial conjunctivitis

NTC has shared positive results from the Phase II MIRAKLE study evaluating the efficacy and tolerability of NTC014 (quinolone antibiotic + NSAID in eye drops solution) in the treatment of bacterial conjunctivitis in adults.  The results show the non-inferiority of NTC014 eye drops vs. antibiotic alone in… Read More

#News

GBP pound sterling funding
#Antibiotic resistance #Antimicrobial resistance (AMR) #Financing #Funding #Glox Therapeutics

£1 million PACE grant to accelerate precision antibiotics 

Glox Therapeutics has secured £1 million in grant funding from Pathways to Antimicrobial Clinical Efficacy (PACE), one of the UK’s largest public-private initiatives targeting early-stage antimicrobial medicines and diagnostic discovery.   The funding will help to accelerate the development of Glox Therapeutics’ novel antibiotics targeting drug-resistant pathogenic bacteria, Escherichia coli… Read More

#Business & Investment #News

Hydrogel
#Antibiotic resistance #Antibiotics #Antimicrobial resistance (AMR) #Bacteria #Chalmers University of Technology #Hydrogel

Hydrogel enhances antibiotics’ effect against resistant bacteria

New research has shown that resistant bacteria can regain susceptibility to antibiotics when the treatment is combined with a material equipped with antibacterial peptides. The study, performed in a laboratory environment, shows that antibiotics can achieve a 64-fold increase in bactericidal effect when used together with… Read More

#News #Trending News

Acinetobacter baumannii
#Antibiotic resistance #Antimicrobial resistance (AMR) #Bacteriophage #Phage therapy

Superbug map supports ‘off-the-shelf’ region-specific phage therapies

Scientists have created a global ‘superbug map’ for one of the most dangerous superbug species, Acinetobacter baumannii, which will aid the development of lifesaving bacteriophage (phage) therapies. In a paper published in the journal Cell, an international collaboration led by scientists at the… Read More

#News

Antibiotics
#Antibiotic resistance #Antibiotics #Antimicrobial resistance (AMR) #Immunology / Virology & Vaccines #World Health Organization

Better use of vaccines will reduce AMR deaths, report finds

Vaccines against 24 pathogens could reduce the number of antibiotics needed by 22% every year, according to a new report by the World Health Organization (WHO). While some of these vaccines are already available but underused, others would need to be developed and brought to the… Read More

#News #Trending News

Destruction of a bacterium by silver nanoparticles.
#Antibiotic resistance #Antimicrobial resistance (AMR) #Bacteria #EVŌQ Nano #Nanopharmaceutics

Silver nanoparticle destroys bacteria from the inside

New data indicates EVŌQ Nano’s nanoparticle EVQ-218 could combat the world’s worst superbugs without triggering antimicrobial resistance (AMR). Bacteria’s ability to form biofilms is a key factor in their resistance to antibiotics. Biofilms are protective layers that shield bacteria from therapeutic interventions and… Read More

#Editor's Choice #News

Bacteria in Petri dishes
#Antibiotic resistance #Antibiotics #Antimicrobial resistance (AMR) #Bacteria #The University of Manchester

New understanding of bacteria mutation rates could combat AMR

Scientists have discovered a way to control mutation rates in bacteria, introducing the possibility of new strategies to combat antimicrobial resistance (AMR). The researchers used high-performance computing to simulate more than 8,000 years of bacterial evolution, allowing scientists to predict mechanisms that control mutation rates. Read More

#Editor's Choice #News

#Antibiotic resistance #Antibiotics #Antimicrobial resistance (AMR) #Interview

Why more work is needed to fight antimicrobial resistance

Reece Armstrong speaks to Professor Janet Hemingway CBE about current efforts in tackling antimicrobial resistance. The threat of AMR has been well documented in recent years. Perhaps the most notable effort came from the 2014 report “The Review on Antimicrobial Resistance” which was chaired by Lord Jim O’Neill and which… Read More

#Exclusive Content

Bacteria in Petri dishes
#Antibiotic resistance #Antibiotics #Antimicrobial resistance (AMR) #GSK #Phase III trial

GSK announces positive data for gonorrhoea antibiotic

Positive results have been announced by GSK for its antibiotic targeting uncomplicated urogenital gonorrhoea (GC) in adolescents and adults. First results from the EAGLE-1 Phase III trial for gepotidacin show that two oral doses of the antibiotic displayed superior success rates (92.6%) when compared to the… Read More

#Editor's Choice #News